It has been shown recently that the expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of this molecule was associated with a shorter progression-free survival/overall survival (27). Here, PDCD1 is linked to non-small cell lung carcinoma.